Announced
Completed
Financials
Tags
Single Bidder
Friendly
Biotechnology
Acquisition
cancer curing
United States
Completed
Majority
Public
Domestic
Synopsis
Gilead Science, an American biopharmaceutical company, completed the acquisition of Kite Pharma, a developer of cancer immunotherapy products, for $11.9bn. “We are excited to welcome more than 700 talented Kite employees to the Gilead organization. Throughout our respective histories, each company has demonstrated a deep commitment to advancing life-saving therapies for people who need them. I look forward to all that we will accomplish together, as a combined organization,” John F. Milligan, Gilead President and Chief Executive Officer.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.